Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential effects of viremia and microbial translocation on immune activation in HIV-infected patients throughout ritonavir-boosted darunavir monotherapy.
BenMarzouk-Hidalgo OJ, Torres-Cornejo A, Gutiérrez-Valencia A, Ruiz-Valderas R, Viciana P, López-Cortés LF. BenMarzouk-Hidalgo OJ, et al. Among authors: viciana p. Medicine (Baltimore). 2015 May;94(17):e781. doi: 10.1097/MD.0000000000000781. Medicine (Baltimore). 2015. PMID: 25929922 Free PMC article.
Immune activation throughout a boosted darunavir monotherapy simplification strategy.
BenMarzouk-Hidalgo OJ, Torres-Cornejo A, Gutiérrez-Valencia A, Ruiz-Valderas R, Viciana P, López-Cortés LF. BenMarzouk-Hidalgo OJ, et al. Among authors: viciana p. Clin Microbiol Infect. 2014 Dec;20(12):1297-303. doi: 10.1111/1469-0691.12521. Epub 2014 Feb 10. Clin Microbiol Infect. 2014. PMID: 24372830 Free article.
Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
Torres-Cornejo A, Ruiz-Valderas R, Jimenez-Jimenez L, Abad-Molina C, Gutierrez-Valencia A, Viciana P, Lopez-Cortes LF. Torres-Cornejo A, et al. Among authors: viciana p. J Viral Hepat. 2014 Mar;21(3):178-88. doi: 10.1111/jvh.12128. Epub 2013 Jul 17. J Viral Hepat. 2014. PMID: 24438679
Low concordance and resistance mutation emergence in the HIV protease gene among circulating and cell-associated viruses at viral replication episodes during darunavir/ritonavir monotherapy.
Torres-Cornejo A, Benmarzouk-Hidalgo OJ, Gutierrez-Valencia A, Ruiz-Valderas R, Viciana P, López-Cortés LF. Torres-Cornejo A, et al. Among authors: viciana p. HIV Med. 2015 Jan;16(1):57-61. doi: 10.1111/hiv.12170. Epub 2014 Jun 9. HIV Med. 2015. PMID: 24913409 Free article.
Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.
Marin-Niebla A, Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Mata R, Gutierrez A, Pascual R, Rodriguez M. Marin-Niebla A, et al. Among authors: viciana p. Antimicrob Agents Chemother. 2007 Jun;51(6):2035-42. doi: 10.1128/AAC.01136-06. Epub 2007 Mar 19. Antimicrob Agents Chemother. 2007. PMID: 17371813 Free PMC article. Clinical Trial.
Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patients.
Lopez-Cortes LF, Ruiz-Valderas R, Sánchez-Rivas E, Lluch A, Gutierrez-Valencia A, Torres-Cornejo A, Benmarzouk-Hidalgo OJ, Viciana P. Lopez-Cortes LF, et al. Among authors: viciana p. Antimicrob Agents Chemother. 2013 Aug;57(8):3746-51. doi: 10.1128/AAC.00315-13. Epub 2013 May 28. Antimicrob Agents Chemother. 2013. PMID: 23716055 Free PMC article.
234 results